These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33707177)

  • 21. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.
    Pereira VC; Malfetano FR; Meira ID; Souza LF; Liem AM; Maiolino A; Alves-Leon SV
    Arq Neuropsiquiatr; 2012 Oct; 70(10):774-9. PubMed ID: 23060103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
    Meca-Lallana JE; Balseiro JJ; Lacruz F; Guijarro C; Sanchez O; Cano A; Costa-Frossard L; Hernández-Clares R; Sanchez-de la Rosa R;
    J Neurol Sci; 2012 Apr; 315(1-2):123-8. PubMed ID: 22133480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy.
    Hellwig K; Thiel S; Haben S; Ciplea AI; Kurzeja A
    Neurodegener Dis Manag; 2023 Aug; 13(4):223-234. PubMed ID: 37382065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis.
    Hewes D; Tatomir A; Kruszewski AM; Rao G; Tegla CA; Ciriello J; Nguyen V; Royal W; Bever C; Rus V; Rus H
    Exp Mol Pathol; 2017 Apr; 102(2):191-197. PubMed ID: 28109694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages.
    Melendez-Torres GJ; Armoiry X; Court R; Patterson J; Kan A; Auguste P; Madan J; Counsell C; Ciccarelli O; Clarke A
    BMC Neurol; 2018 Oct; 18(1):162. PubMed ID: 30285675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
    Dabbaghi R; Safaralizadeh R; Rahmani S; Barpour N; Hosseinpourfeizi M; Rajabi A; Baradaran B
    BMC Res Notes; 2023 Oct; 16(1):273. PubMed ID: 37845751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
    Tao Y; Zhang X; Markovic-Plese S
    J Neuroimmunol; 2016 Sep; 298():181-8. PubMed ID: 27609294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.
    Peterka M; Valis M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Klimova B; Stourac P; Pavelek Z; Novotny M
    Eur Neurol; 2023; 86(5):334-340. PubMed ID: 37473734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
    Darbà J; Kaskens L; Sánchez-de la Rosa R
    J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.
    Schreiber H; Hipp J; Roßnagel F; Moritz C
    Neurodegener Dis Manag; 2023 Oct; 13(5):281-288. PubMed ID: 37909320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    Kapica-Topczewska K; Tarasiuk J; Collin F; Brola W; Chorąży M; Czarnowska A; Kwaśniewski M; Bartosik-Psujek H; Adamczyk-Sowa M; Kochanowicz J; Kułakowska A
    PLoS One; 2019; 14(10):e0223863. PubMed ID: 31647829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
    Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
    Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA-A Preliminary Study.
    Reyes-Mata MP; Mireles-Ramírez MA; Griñán-Ferré C; Pallàs M; Pavón L; Guerrero-García JJ; Ortuño-Sahagún D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
    Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
    Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.
    Jongen PJ; Lehnick D; Sanders E; Seeldrayers P; Fredrikson S; Andersson M; Speck J;
    Health Qual Life Outcomes; 2010 Nov; 8():133. PubMed ID: 21078142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.